S3-Leitlinien Demenzen

Zusammenfassung

Die Therapie der Demenzen umfasst eine pharmakologische Behandlung und psychosoziale Interventionen für Patienten und Angehörige im Kontext eines symptom- und schweregradabhängigen Gesamtbehandlungsplans. Primäres Ziel ist die Behandlung der Kernsymptomatik kognitive Störungen, ADL-Defizite und, falls notwendig, Therapie der psychischen und Verhaltenssymptome. Evidenzbasiert ist die stadiumabhängige Behandlung der AD mit AChE-I und Memantin. Die höchste verträgliche Dosis sollte angestrebt werden sowie eine kontinuierliche Langzeittherapie. Es ist gerechtfertigt, eine gemischte Demenz wie eine AD zu behandeln. Die Behandlung der VD mit einem AChE-I oder Memantin ist eine Off-label-Behandlung ohne vollständig überzeugenden Wirksamkeitsbeleg. Es gibt keine Evidenz zur Behandlung kognitiver Symptome oder Verhaltenssymptome bei Patienten mit FTD oder LKD. Für die antidementive Behandlung der PD ist Rivastigmin wirksam und zugelassen.

Summary

The treatment of dementia comprises a pharmacological treatment and psychosocial interventions for patients and families in the context of a symptom and severity-dependent overall treatment plan. The primary goal is to treat the core symptoms cognitive impairment, ADL deficits and, if necessary, treatment of mental and behavioral symptoms. The stage-dependent treatment of AD with AChE-I and memantine is evidencebased. The highest tolerated dose should be targeted as well as a long-term treatment. Mixed dementia should be treated like AD. The treatment of VD with AChE-I or memantine is an off-label treatment without convincing efficacy. There is no evidence for the treatment of cognitive symptoms or behavioral symptoms in patients with FTD or LBD. Rivastigmine is effective and approved as antidementia drug in PD.

Schlüsselwörter

Alzheimer - S3-Leitlinien - symptomatische Therapie

Keywords

Alzheimer - S3-Guidelines - symptomatic therapy

• Literatur

• 1 CHMP. Guideline on medicinal products for the treatment of Alzheimer’s Disease and other dementias. Doc. Ref. CPMP/EWP/553/95 Rev. 1. London: European Medicines Agency; 2008
• 2 Winblad B, Engedal K, Soininen H. et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57 (03) 489-95.
• 3 Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006; 01: CD005593.
• 4 IQWiG. Cholinesterasehemmer bei Alzheimer-Demenz. Abschlussbericht A05–19A. Köln: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2007
• 5 Farlow MR. et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: A 24-week, randomized, doubleblind study. Clin Ther 2010; 32 (07) 1234-51.
• 6 Winblad B, Grossberg G, Frolich L. et al. IDEAL: a 6-month, double-blind, placebo-ontrolled study of the first skin patch for Alzheimer disease. Neurology 2007; 69 (4 Suppl 1): 14-22.
• 7 Winblad B, Engedal K, Soininen H. et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57 (03) 489-95.
• 8 Emre M. Switching cholinesterase inhibitors in patients with Alzheimer’s disease. Int J Clin Pract 2002; 127 (Suppl): 64-72.
• 9 Gauthier S, Emre M, Farlow MR. et al. Strategies for continued successful treatment of Alzheimer’s disease: switching cholinesterase inhibitors. Curr Med Res Opin 2003; 19 (08) 707-14.
• 10 Burns A, Bernabei R, Bullock R. et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer’s disease (the SERAD study): A randomised, placebo-controlled, double-blind trial. Lancet Neurol 2009; 08 (01) 39-47.
• 11 Rountree SD. et al. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther 2009; 01 (02) 7.
• 12 Daiello LA, Ott BR, Lapane KL, Reinert SE, Machan JT, Dore DD. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. Am J Geriatr Pharmacother 2009; 07 (02) 74-83.
• 13 Doody RS. et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer’s disease. Dement Geriatr Cogn Disord 2001; 12 (04) 295-300.
• 14 Holmes C. et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004; 63 (02) 214-9.
• 15 Pariente A. et al. Effect of treatment gaps in elderly patients with dementia treated with cholinesterase inhibitors. Neurology 2012; 78 (13) 957-63.
• 16 Emre M. Switching cholinesterase inhibitors in patients with Alzheimer’s disease. Int J Clin Pract 2002; 127 (Suppl): 64-72.
• 17 Winblad B, Jones RW, Wirth Y. et al. Memantine in moderate to severe Alzheimer’s disease: a metaanalysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007; 24 (01) 20-7.
• 18 Raina P. et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008; 148 (05) 379-97.
• 19 Tariot PN, Farlow MR, Grossberg GT. et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Jama 2004; 291 (03) 317-24.
• 20 Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, doubleblind, placebocontrolled trial. Curr Alzheimer Res 2008; 05 (01) 83-9.
• 21 IQWiG. Memantin bei Alzheimer Demenz Abschlussbericht A05–19D. Köln: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2009
• 22 Howard R. et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med 2012; 366 (10) 893-903.
• 23 Gill SS, Anderson GM, Fischer HD. et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a populationbased cohort study. Arch Intern Med 2009; 169 (09) 867-73.
• 24 Birks J, Grimley JEvans. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2009; 01: CD003120.
• 25 Vellas B. et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 2012; 11 (10) 851-9.
• 26 Boothby LA, Doering PL. Vitamin C and vitamin E for Alzheimer’s disease. Ann Pharmacother 2005; 39 (12) 2073-80.
• 27 Isaac MG, Quinn R, Tabet N. Vitamin E for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev 2008; 03: CD002854.
• 28 Tabet N, Feldman H. Indomethacin for the treatment of Alzheimer’s disease patients. Cochrane Database Syst Rev 2002; 02: CD003673.
• 29 Tabet N, Feldman H. Ibuprofen for Alzheimer’s disease. Cochrane Database Syst Rev 2003; 02: CD004031.
• 30 Aisen PS, Schafer KA, Grundman M. et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003; 289 (21) 2819-26.
• 31 Martin BK, Szekely C, Brandt J. et al. Cognitive function over time in the Alzheimer’s Disease Antiinflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 2008; 65 (07) 896-905.
• 32 Reines SA, Block GA, Morris JC. et al. Rofecoxib: no effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology 2004; 62 (01) 66-71.
• 33 Scharf S, Mander A, Ugoni A. et al. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease. Neurology 1999; 53 (01) 197-201.
• 34 Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord 2004; 17 (04) 355-9.
• 35 AWMF. 2009 S3-Leitlinie IS. Hormontherapie in der Peri- und Postmenopause (HT). AWMF 015/062.
• 36 Farquhar C, Marjoribanks J, Lethaby A. et al. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database 2009; Syst Rev 02: CD004143.
• 37 Gabriel SR, Carmona L, Roque M. et al. Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2005; 02: CD002229.
• 38 Birks J, Flicker L. Selegiline for Alzheimer’s disease. Cochrane Database Syst Rev 2003; 01: CD000442.
• 39 Fioravanti M, Flicker L. Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst 2001; Rev 04: CD003159.
• 40 Flicker L, Grimley GEvans. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev 2001; 02: CD001011.
• 41 Higgins JP, Flicker L. Lecithin for dementia and cognitive impairment. Cochrane Database Syst Rev 2003; 03: CD001015.
• 42 Lopez-Arrieta JM, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev 2002; 03: CD000147.
• 43 Olin J, Schneider L, Novit A, Luczak S. Hydergine for dementia. Cochrane Database Syst Rev 2001; 02: CD000359.
• 44 Alvarez XA, Cacabelos R, Laredo M. et al. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer’s disease. Eur J Neurol 2006; 13 (01) 43-54.
• 45 Wei ZH, He QB, Wang H. et al. Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer’s disease. J Neural Transm 2007; 114 (05) 629-34.
• 46 Enache D, Winblad B, Aarsland D. Depression in dementia: epidemiology, mechanisms, and treatment. Curr Opin Psychiatry 2011; 24 (06) 461-72.
• 47 Bergh S. et al. Discontinuation of antidepressants in people with dementia and neuropsyvhiatric symptomes (DESEP study): double blind, randomiesed, parallel group, placebo controlled trial. BMJ 2012; 344: e1566.
• 48 Banerjee S. et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 2011; 378 (9789): 403-11.
• 49 Woolcott JC, Richardson KJ, Wiens MO, Patel B, Marin J, Khan KM, Marra CA. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 2009; 169 (21) 1952-60.
• 50 Vieweg WV, Wood MA, Fernandez A, Beatty-Brooks M, Hasnain M, Pandurangi AK. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging 2009; 26 (12) 997-1012.
• 51 Deshmukh A, Ulveling K, Alla V, Abuissa H, Airey K. Prolonged QTc interval and torsades de pointes induced by citalopram. Tex Heart Inst J 2012; 39 (01) 68-70.
• 52 Ballard C, Creese B, Corbett A, Aarsland D. Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert Opin Drug Saf 2011; 10 (01) 35-43.
• 53 Trifirò G, Gambassi G, Sen EF, Caputi AP, Bagnardi V, Brea J, Sturkenboom MC. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested casecontrol study. Ann Intern Med 2010; 152 (07) 418-25.
• 54 Ballard C. et al. A randomised, blinded, placebocontrolled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Med 2008; 05 (04) e76.
• 55 Kales HC. et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry 2012; 169 (01) 71-9.
• 56 Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, Lucas JA, Schneeweiss S. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ 2012; 344: e977.
• 57 Vigen CL. et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD. Am J Psychiatry 2011; 168 (08) 831-9.
• 58 Diener H-C, Putzki N. (Hrsg.). Primär- und Sekundärprävention der zerebralen Ischämie. Leitlinien für Diagnostik und Therapie in der Neurologie. 4. überarb Aufl. Stuttgart: Thieme; 2008
• 59 Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007; 06 (09) 782-92.
• 60 Williams PS, Rands G, Orrel M, Spector A. Aspirin for vascular dementia. Cochrane Database Syst Rev 2000; 04: CD001296.
• 61 Meyer JS, Rogers RL, McClintic K. et al. Randomized clinical trial of daily aspirin therapy in multiinfarct dementia. A pilot study. J Am Geriatr Soc 1989; 37 (06) 549-55.
• 62 Erkinjuntti T, Kurz A, Gauthier S. et al. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359 (9314): 1283-90.
• 63 Kertesz A, Morlog D, Light M. et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord 2008; 25 (02) 178-85.
• 64 Deakin JB, Rahman S, Nestor PJ. et al. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology 2004; 172 (04) 400-8.
• 65 Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord 2004; 17 (04) 355-9.
• 66 Poewe W, Gauthier S, Aarsland D. et al. Diagnosis and management of Parkinson’s disease dementia. Int J Clin Pract 2008; 62 (10) 1581-7.
• 67 Emre M, Aarsland D, Albanese A. et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351 (24) 2509-18.
• 68 Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson’s disease dementia. Cochrane Database Syst Rev 2006; 01: CD004747.
• 69 McKeith I, Del Ser T, Spano P. et al. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study. Lancet 2000; 356 (9247): 2031-6.
• 70 Wild R, Pettit T, Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev 2003; 03: CD003672.